Sunday 18 October 2026
Export NXL’s income statement to Excel — free account
Nexalin Technology, Inc.
NXL Healthcare Medical Devices
Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024. In the quarter to June 2026, revenue fell 82.7%, EPS fell 10.0% and free cash flow fell 97.2%, each against the same quarter a year earlier.
2.35
0.10
−4.08%
Follow NXL
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 4 | 3 | 4 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(26.89) | (5.22) | (29.65) | (12.11) | — | — | — |
P/S ratio |
30.30 | 150.63 | 26.43 | 3.31 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(68.21) | (65.32) | (66.35) | (25.63) | (374.17) | (2,045.67) | (2,004.13) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.86) | (6.22) | 13.29 | 4.76 | (30.87) | (103.50) | — |
P/Operating CF |
(7.96) | (22.40) | (2.91) | (4.82) | (67.87) | (67.87) | (67.87) |
P/B ratio |
2.44 | 6.91 | 0.91 | 0.80 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
2.68 | 7.44 | 0.94 | 0.80 | 0.00 | 0.00 | 0.00 |
EV/Sales |
17.97 | 130.03 | (0.16) | (1.98) | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 1.43 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.09) | (5.56) | 0.00 | 1.18 | (7.58) | (7.58) | (7.58) |
EV/FCF |
(0.45) | (1.99) | 0.00 | 1.18 | (7.58) | (7.58) | (7.58) |
Quick Ratio |
4.29 | 6.39 | 6.95 | 3.59 | 0.29 | 0.05 | 0.07 |
Current Ratio |
4.85 | 7.25 | 8.06 | 3.81 | 0.32 | 0.07 | 0.11 |
Net Debt/EBITDA |
0.44 | 0.45 | 0.52 | 3.82 | 0.11 | 0.02 | (0.53) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.56% | 744.18% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.71) |
Asset Turnover |
0.07 | 0.04 | 0.02 | 0.32 | 0.33 | 2.10 | 0.00 |
Operating CF/Net income |
0.60 | 0.52 | 0.83 | 1.31 | 0.18 | 0.25 | 0.14 |
Capex/Depreciation |
(4.51) | (11.28) | (27.81) | (13,589.80) | 0.00 | (0.06) | 0.00 |
Interest Coverage |
1,023.28 | 2,423.31 | (146.81) | (30.86) | (73.13) | (41.87) | (36.20) |
| (221.50%) | (221.06%) | (107.05%) | (89.43%) | 371.49% | 245.77% | 0.00% | |
| (185.64%) | (193.70%) | (84.03%) | (41.48%) | (1,393.72%) | (2,946.75%) | 0.00% | |
ROIC |
(21,146.42%) | (2,471.51%) | (1,378.85%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(240.98%) | (222.80%) | (154.72%) | (31.00%) | 377.54% | 235.03% | 540.26% |
Average Days of Receivables |
98.75 | 28.13 | 30.99 | 1.35 | 41.29 | 9.92 | 10.03 |
Research and Development Expense of Revenue |
359.25% | 705.93% | 1,736.04% | 38.67% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
2,502.52% | 3,969.12% | 3,486.45% | 211.23% | 4,261.76% | 1,429.52% | 701.69% |
Intangible Assets out of Total Assets |
0.07 | 0.06 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,035.58% | 2,110.55% | 2,180.13% | 20.49% | 3,107.56% | 806.71% | 0.00% |
Graham Net Nets |
0.37 | 0.13 | 1.03 | 1.25 | 0.01 | 0.01 | 0.01 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(91.49%) | (29.74%) | (155.93%) | (40.15%) | (56.69%) | (56.69%) | (56.69%) |
Free Cash Flow Yield |
(131.04%) | (43.42%) | (370.76%) | (50.69%) | (13.10%) | (13.10%) | (13.10%) |
Revenue per Share |
0.55 | 0.55 | 0.45 | 7.12 | 1.02 | 2.04 | 0.03 |
Operating CF per Share |
(9.08) | (12.85) | (15.65) | (11.94) | (7.60) | (7.24) | (0.09) |
Capex per Share |
(0.18) | (0.55) | (0.49) | (36.61) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(9.26) | (13.41) | (16.14) | (48.55) | (7.60) | (7.24) | (0.09) |
Cash per Share |
6.82 | 11.34 | 12.03 | 37.68 | 4.67 | 0.66 | 0.01 |
Shareholders Equity per Share |
6.87 | 11.98 | 13.09 | 29.52 | (11.87) | (13.33) | (0.16) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.87 | 11.98 | 13.09 | 29.52 | (11.87) | (13.33) | (0.16) |
Free Cash Flow |
(5.05) | (4.11) | (3.95) | (9.01) | (1.08) | (0.86) | (0.68) |
Working Capital |
3.41 | 3.41 | 3.00 | 5.48 | (1.61) | (1.45) | (0.93) |
Capital Expenditures |
(0.10) | (0.17) | (0.12) | (6.79) | — | 0.00 | — |
Net Current Asset Value |
3.41 | 3.41 | 3.00 | 5.47 | (1.68) | (1.59) | (1.18) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 1.43 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.32 | 1.01 | 1.08 | 5.14 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 1.00 | 0.50 | 5.81 | 0.36 |
Cash ROIC |
(67.65%) | (57.50%) | (64.26%) | (72.24%) | 105.56% | 57.36% | 243.29% |
Accounts Receivable Turnover |
6.38 | 15.06 | 15.48 | 124.66 | 12.59 | 39.50 | 0.00 |
Accounts Payable Turnover |
0.31 | 0.23 | 0.06 | 0.48 | 0.03 | 0.07 | 0.00 |
Inventory Turnover |
0.40 | 0.22 | 0.17 | 3.91 | 0.79 | 1.31 | 0.00 |
Average Days of Payables |
1,454.06 | 1,554.74 | 2,265.27 | 661.66 | 14,391.92 | 5,804.76 | 542.82 |
Days of Inventory on Hand |
781.72 | 1,741.23 | 2,221.25 | 155.17 | 535.56 | 285.71 | 36.13 |
Average Receivables |
0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — |
Average Payables |
0.20 | 0.16 | 0.41 | 0.75 | 0.65 | 0.39 | — |
Average Inventory |
0.15 | 0.17 | 0.16 | 0.09 | 0.03 | 0.02 | — |
Average Assets |
4.43 | 3.93 | 5.53 | 4.09 | 0.44 | 0.12 | — |
Average Common Equity |
3.71 | 3.44 | 4.34 | 1.90 | (1.64) | (1.38) | — |
Columns are period end dates · fundamentals updated 2 Oct 2026